Lightbridge Corporation — Q1 2015 Form 10-Q
Business context and period: Unaudited results for the three months ended March 31, 2015, compared with Q1 2014. Lightbridge develops metallic nuclear-fuel technology and provides nuclear consulting services. All reported revenue in both periods came from consulting; the fuel technology business remained in research and development.
Key financial results
| Metric | Q1 2015 | Q1 2014 / prior date |
|---|---|---|
| Consulting revenue | $123,895 | $254,107 |
| Cost of consulting services | $57,391 | $125,012 |
| Gross profit (margin) | $66,504 (54%) | $129,095 (51%) |
| Operating expenses | $1,144,474 | $1,563,405 |
| Operating loss | $1,077,970 | $1,434,310 |
| Net loss | $1,080,324 | $1,433,922 |
| Basic and diluted loss per share | $0.06 | $0.10 |
| Net cash used in operating activities | $1,029,233 | $1,469,206 |
| Cash and cash equivalents | $3,171,530 | $4,220,225 at Dec. 31, 2014 |
| Restricted cash | $325,341 | $325,181 at Dec. 31, 2014 |
| Total assets | $4,987,610 | $6,053,236 at Dec. 31, 2014 |
| Current liabilities | $586,685 | $653,669 at Dec. 31, 2014 |
There was no debt or credit line reported. Cash and restricted cash totaled about $3.5 million at quarter-end. The company reported approximately $3.5 million in working capital, but said it did not expect that amount to fund operations for the next 12 months at its then-current burn rate. Operating cash outflow was partly offset by $19,302 of patent costs; financing cash outflow was $160.
Changes versus Q1 2014
- Revenue fell 51% (about $130,000), primarily because work for ENEC and FANR declined by approximately $300,000; higher Lloyd’s Register consulting revenue partially offset the drop.
- Gross profit decreased about 48%, although gross margin rose to 54% from 51% as consulting costs fell proportionally more than revenue.
- Operating expenses declined about $419,000: general and administrative costs fell 18%, and research and development costs fell 51%, largely reflecting reduced payroll and R&D labor costs.
- Net loss narrowed by approximately $354,000. Operating cash use also decreased by about $440,000 year over year.
Outlook, risks and unusual items
- Funding and liquidity: Management estimated a cash-flow shortfall of approximately $450,000 per month over the next 12 months and said working capital was insufficient to fund that period. It was seeking equity, strategic investment/alliance funding, or new consulting work; it could also delay expenses. Management warned that without new consulting or strategic technology agreements it would need to raise capital in 2015, and that failure to raise capital in the next 9–12 months could prevent execution of its current plan.
- Development spending and milestones: The company expected to spend approximately $3 million on fuel R&D over the next 12–15 months. It planned sample fabrication with Canadian Nuclear Laboratories, irradiation testing at Norway’s Halden reactor, and expected initial major test results in late 2017 or early 2018. These are plans and estimates, not assured outcomes.
- Program and regulatory risks: Russia-related disruption had shifted critical work to Canada and Norway. Shipment to Norway depended on renewal of the U.S.–Norway 123 Agreement; failure to renew it in time could delay the program. Commercial deployment also depends on successful testing, regulatory approvals, fuel-fabrication capability, and industry acceptance.
- Revenue concentration: ENEC and FANR accounted for about 34% of Q1 2015 revenue, versus 86% in Q1 2014; Lloyd’s Register accounted for 58% of Q1 2015 revenue. FANR’s contract was extended through 2016 and ENEC’s through 2015, but future work and revenue depend on agreed work plans.
- Litigation: Former CFO James D. Guerra filed state-court and OSHA complaints alleging defamation, unpaid paid time off, and retaliation. The state complaint sought at least $1 million in compensatory damages, $1 million in punitive damages, and at least $15,507.19 for paid time off; the OSHA complaint did not specify damages. The company denied the claims and said it would defend itself.
- Potential dilution: At March 31, 4,886,764 warrants and 1,912,157 options were outstanding. The board approved a 3 million-share 2015 equity plan, subject to shareholder ratification, and additional option grants were made in April 2015.
- Other risks: The filing highlights dependence on international operations and a small number of consulting clients, competition and nuclear-industry sentiment, intellectual-property and export-control issues, and the need to secure additional financing. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor verification points
- Confirm current cash runway, monthly burn, and whether subsequent financing, strategic partnerships, or consulting awards addressed the disclosed funding gap.
- Track ENEC, FANR, and Lloyd’s Register work plans, contract extensions, revenue contribution, and receivable collection.
- Verify progress, cost, and regulatory/export authorization for fuel fabrication and irradiation testing, including the status of the U.S.–Norway 123 Agreement.
- Review the status and potential exposure of the former CFO’s court and OSHA claims.
- Assess dilution from outstanding warrants and options, the shareholder vote on the 2015 equity plan, and the April 2015 option grants.